Company intelligence
UT MD Anderson
About UT MD Anderson
The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. Its sole mission is to end cancer for patients and their families around the world. UT MD Anderson provides cancer care in Houston’s Texas Medical Center, as well as several locations throughout the Greater Houston Area. UT MD Anderson also collaborates with hospitals, health systems and organizations across the U.S. and around the world to advance our mission to end cancer. UT MD Anderson was created in 1941 as part of The University of Texas System, and, in 1971, it became one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971. U.S. News & World Report’s “Best Hospitals” rankings has named UT MD Anderson the nation's top hospital for cancer care. The institution has been named one of the nation’s top two hospitals for cancer care every year since the survey began in 1990. The recognition reflects the passion of our 27,000 extraordinary employees and 1,000 volunteers for providing exceptional care to our patients and their families, and for realizing our mission to #EndCancer. You can view all of our career opportunities at Careers.MDAnderson.Org.
Verified activity
Signals from UT MD Anderson
31 published signals
People
UT MD Anderson named Nati McWilliams, CFRE as Senior Vice President and Chief Philanthropy Officer.
Reported by UT MD Anderson
Capital & Finance
UT MD Anderson recorded $386 million in fundraising following a record year in FY25.
Reported by UT MD Anderson
Presence & Recognition
UT MD Anderson hosted the PRiSMlab lab retreat in the Texas Hill country for 4 days of hackathon, project development, grant writing, hiking, swimming, cooking, eating, and team building.
Reported by Heiko Enderling
Presence & Recognition
UT MD Anderson announced the launch of a new screening activity for anxiety and depression.
Reported by eduardo bruera
Operations & Supply
UT MD Anderson reported on the acute-palliative-care-unit-discharge-outcomes activity.
Reported by eduardo bruera
Research & Knowledge
UT MD Anderson researchers published a challenge to the long-held thought about peripheral neuropathy in colorectal cancer patients and antitumor activity from an oral RAS-inhibitor therapy for some lung cancer patients.
Reported by UT MD Anderson
Research & Knowledge
UT MD Anderson researchers led by Tina Cascone, M.D., Ph.D., found that ctDNA clearance and MRD status may help identify which patients with resectable non-small cell lung cancer get the greatest benefit from immunotherapy given before and after surgery.
Reported by UT MD Anderson
Research & Knowledge
UT MD Anderson researchers led by Shao-Rui Chen, M.D., and Hui-Lin Pan, M.D., Ph.D., found new evidence that BRAF plays a key role in chronic pain caused by nerve damage.
Reported by UT MD Anderson
Research & Knowledge
UT MD Anderson researchers led by Michael Andreeff, M.D., Ph.D., and Yuki Nishida, M.D., Ph.D., showed preclinical findings in a study that demonstrated strong anti-cancer activity from a first-in-class therapy to target MYC, a protein involved in about 70% of cancers.
Reported by UT MD Anderson
Research & Knowledge
UT MD Anderson researchers led by David S. Hong, MD, in a Phase 1/2 trial, found that Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients.
Reported by UT MD Anderson
Research & Knowledge
UT MD Anderson researchers led by Bryan Valcarcel, MD, MPH, and Luis Malpica Castillo, M.D., found that Hodgkin lymphoma survivors face higher death risk requiring comprehensive survivorship care focused on cardiovascular health, secondary cancers, and other chronic conditions.
Reported by UT MD Anderson
Research & Knowledge
UT MD Anderson researchers led by Andrew Shepherd, Ph.D., found that nerve damage in colorectal cancer may be present because of the cancer itself rather than chemotherapy treatment.
Reported by UT MD Anderson
Presence & Recognition
UT MD Anderson employee Eduardo Bruera participated in a person-centered care planning and palliative activity.
Reported by eduardo bruera
Presence & Recognition
UT MD Anderson hosted a Leukemia PharmD Appreciation luncheon to reflect on contributions of oncology and research efforts.
Reported by Naveen Pemmaraju, MD
Research & Knowledge
UT MD Anderson announced that the 2026 AmerUrological NMIBC Guidelines classified all high-grade Ta tumors as high-risk.
Reported by Ashish Kamat, MD
Strategy & Corporate Development
UT MD Anderson is a leading provider of medical oncology services across the United States.
Reported by eduardo bruera
Research & Knowledge
UT MD Anderson published a scoping review of breakthrough cancer pain activity.
Reported by eduardo bruera
Presence & Recognition
UT MD Anderson was recognized by Becker's Hospital Review as a smart hospital to know.
Reported by UT MD Anderson
Presence & Recognition
UT MD Anderson announced that the inaugural Clinical Nutrition Symposium for MD Anderson's inaugural Clinical Nutrition Symposium closes in 7 days on September 10.
Reported by Lori Chang, MS, RD, CSCS, ACC, CPC, ELI-MP
Presence & Recognition
UT MD Anderson hosted the Understanding Our Innovations seminar featuring Rafael Casellas, Ph.D., Professor in Hematopoietic Biology and Malignancy.
Reported by Eyal Gottlieb
Presence & Recognition
UT MD Anderson clinical ethics team member Gavin Enck described how clinical ethics fits into cancer care at UT MD Anderson and how the team provides support.
Reported by UT MD Anderson
Research & Knowledge
UT MD Anderson published nearly 4,700 scientific peer-reviewed articles in Fiscal Year 2026.
Reported by Peter Pisters
Research & Knowledge
UT MD Anderson maintained patient safety outcomes that benchmark UT MD Anderson among the best in Fiscal Year 2026.
Reported by Peter Pisters
Research & Knowledge
UT MD Anderson helped fuel 70% of all cancer drugs approved by the FDA in Fiscal Year 2026.
Reported by Peter Pisters